Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2012 | $146 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
BioMotiv, LLC chose not to state its revenue in its newest notice of a funding round (Aug 2018).
SEC Form D · Aug 2018
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2018
That is all the official record says: BioMotiv, LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of BioMotiv, LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 62 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Baiju R. Shah | Chief Executive Officer and Board of Managers | Aug 2018 |
| Charles S. McOsker, Ph.D. | Senior Vice President, Technical Operations | Aug 2018 |
| Jeffrey S. Edelson, MD | Chief Medical Officer | Aug 2018 |
| Mark S. Teague | Chief Financial Officer | Aug 2018 |
| Stacie S. Switzer | Senior Vice President and General Counsel | Aug 2018 |
| Terry S. Vance | Chief Business Officer | Aug 2018 |
| Theodore S. Torphy, Ph.D. | Chief Scientific Officer | Aug 2018 |
| Baiju Shah | Chief Executive Officer and Board of Managers | Aug 2016 |
| Ted S. Torphy, Ph.D. | Chief Scientific Officer | Aug 2016 |
| Terry Vance | Chief Business Officer | Aug 2016 |
| David C. U'Prichard, Ph.D. | Board of Managers and Chair of Advisory Board | Aug 2015 |
| Terry R. Vance | Chief Business Officer | Aug 2013 |
| Baiju R. Shah | Chief Executive Officer and Board of Managers | Aug 2018 |
| Carmen S. Bozic, MD | Board of Managers | Aug 2018 |
| David C. U'Prichard, Ph.D. | Board of Managers and Chair of Advisory Board | Aug 2018 |
| Jonathan S. Stamler, M.D. | Board of Managers | Aug 2018 |
| Michael S. Martin, Ph.D. | Board of Managers | Aug 2018 |
| Robert S. Reitman | Board of Managers | Aug 2018 |
| Ronald G. Harrington | Board of Managers | Aug 2018 |
| Baiju Shah | Chief Executive Officer and Board of Managers | Aug 2016 |
| Carmen S. Bozic, M.D. | Board of Managers | Aug 2016 |
| Graeme S. Martin, Ph.D. | Board of Managers | Aug 2016 |
| Graeme S. Martin | Board of Managers | Aug 2015 |
| Achilles A. Demetriou, M.D., Ph.D. FACS | Board of Managers | Sep 2012 |